

#16

PTOL-413A (05-03)
Approved for use through xx/xx/xxxx. OMB 0661-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Applicant Initiated Interview Request Form

Application No. 09/607,142 First Named Applicant: Joel Cherry
Examiner: C. Mahatan Art Unit: 1631 Status of Application: NON-final

Tentative Participants:

(1) Examiner Mahatan (2) Jason Garbell (attorney)
(3) Joel Cherry (4) _____

Proposed Date of Interview: 7/3/03 Proposed Time: 2:00 (AM/PM) (PM)

Type of Interview Requested:

(1) ☒ Telephonic (2) ☐ Personal (3) ☐ Video Conference

Exhibit To Be Shown or Demonstrated: ☐ YES ☒ NO

If yes, provide brief description: _____

Issues To Be Discussed

Issues (Rej., Obj., etc)	Claims/ Fig. #s	Prior Art	Discussed	Agreed	Not Agreed
(1) <u>§112, 1st</u> <u>enablement</u>	<u>5, 35-40</u>	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(2) <u>§112, 1st</u> <u>w. #w. descrpt.</u>	<u>5, 35</u>	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(3) <u>§112, 2nd</u>	<u>5, 35-40</u>	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(4) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Continuation Sheet Attached

Brief Description of Arguments to be Presented:

Applicants will discuss enablement and written description rejections
with reference to Appendix 1, skill of the artisan & relevant
sections of specification. Applicants will also discuss §112, 2nd issue
but consider possible amendments.

An interview was conducted on the above-identified application on _____.

NOTE:

This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).

This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.

Joel Cherry
(Applicant/Applicant's Representative Signature)

(Examiner/SPE Signature)

This collection of information is required by 37 CFR 1.133. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Attorney Docket No.: 5443.424-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Cherry et al.

Confirmation No: 7060

Serial No.: 09/607,142

Group Art Unit: 1631

Filed: June 29, 2000

Examiner: Mahatan, C.

For: Maltogenic Alpha-Amylase Variants

FAX RECEIVED
JUN 26 2003
GROUP 1600

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

I hereby certify that the attached correspondence comprising:

1. Applicant Initiated Interview Request Form

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Mahatan, C., fax number (703) 308-4242.

Respectfully submitted,

Lourdes Ayala
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Date: June 26, 2003